Recent News for BLRX - BioLineRx Ltd.

Date Title
Sep 26 BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors
Sep 25 BioLineRx advances Phase 1/2a study of cancer candidate AGI-134
Sep 25 BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
Sep 16 BioLineRx (BLRX) Investor Presentation - Slideshow
Sep 4 The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
Sep 3 Healthcare - Top 5 Gainers / Losers
Sep 3 BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
Aug 9 The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2
Aug 8 The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering
Aug 7 The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout
Aug 6 BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q2 2019 Results - Earnings Call Transcript
Aug 6 biolinerx EPS beats by $0.58
Aug 6 BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Aug 2 Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?
Jul 30 BioLineRx to Report Second Quarter 2019 Results on August 6, 2019
Jun 28 BioLineRx reverse splits ADSs 1:15; shares off 3% after hours
Jun 28 BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares
Jun 13 BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference
May 17 BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade
May 14 BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2019 Results - Earnings Call Transcript
May 14 biolinerx EPS in-line
May 14 BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 7 BioLineRx to Report First Quarter 2019 Results on May 14, 2019
May 7 BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors
May 1 Biotech News, What Milestones and Catalysts Could Drive BioLineRx Shares in 2019
Back to the Main BLRX Page...